A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

NCT06858813 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

232

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Cancer
Squamous-Cell Non-Small Cell Lung Cancer

Interventions

DRUG: Lenvatinib
DRUG: ABBV-324

Sponsor

AbbVie